Clinical Trial Update: Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating atezolizumab in combination with chemotherapy for metastatic triple-negative breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tecentriq (atezolizumab)

Snippet

Sponsor: European Institute of Oncology | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING